- Home
- DGICB vs TNGX Comparison
DGICB vs TNGX Comparison
Compare DGICB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- TNGX
- Stock Information
- Founded
- DGICB 1986
- TNGX 2014
- Country
- DGICB United States
- TNGX United States
- Employees
- DGICB N/A
- TNGX N/A
- Industry
- DGICB Property-Casualty Insurers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- TNGX Health Care
- Exchange
- DGICB Nasdaq
- TNGX Nasdaq
- Market Cap
- DGICB 504.0M
- TNGX 413.6M
- IPO Year
- DGICB N/A
- TNGX N/A
- Fundamental
- Price
- DGICB $15.06
- TNGX $2.91
- Analyst Decision
- DGICB
- TNGX Strong Buy
- Analyst Count
- DGICB 0
- TNGX 8
- Target Price
- DGICB N/A
- TNGX $13.14
- AVG Volume (30 Days)
- DGICB 928.0
- TNGX 1.4M
- Earning Date
- DGICB 10-24-2024
- TNGX 11-06-2024
- Dividend Yield
- DGICB 4.12%
- TNGX N/A
- EPS Growth
- DGICB 148.60
- TNGX N/A
- EPS
- DGICB 0.74
- TNGX N/A
- Revenue
- DGICB $979,119,004.00
- TNGX $43,383,000.00
- Revenue This Year
- DGICB N/A
- TNGX $27.73
- Revenue Next Year
- DGICB $5.78
- TNGX N/A
- P/E Ratio
- DGICB $21.91
- TNGX N/A
- Revenue Growth
- DGICB 7.44
- TNGX 15.67
- 52 Week Low
- DGICB $10.75
- TNGX $2.70
- 52 Week High
- DGICB $16.81
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- DGICB 59.65
- TNGX 32.63
- Support Level
- DGICB $14.26
- TNGX $2.70
- Resistance Level
- DGICB $15.90
- TNGX $3.29
- Average True Range (ATR)
- DGICB 0.53
- TNGX 0.29
- MACD
- DGICB -0.02
- TNGX 0.02
- Stochastic Oscillator
- DGICB 31.38
- TNGX 13.91
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.